Resources Repository
-
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Government/Law | Chronic Disease/Risk | Costing Methods | Benefit-Cost Analysis | Policy/Regulation | Health/Medicine | North America -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Government/Law | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Health/Medicine | Europe -
ArticlePublication 2017Cost-Effectiveness of a Policy Strategy to Decrease Sodium Intake: Global Analysis
The objective of this study was to assess the cost effectiveness of a government policy combining …
The objective of this study was to assess the cost effectiveness of a government policy combining targeted industry agreements and public education to reduce sodium intake in 183 countries worldwide. To account for heterogeneity in efficacy across countries, a range of scenarios were evaluated, including 10%, 30%, 0.5 g/day, and 1.5 g/day sodium reductions achieved over 10 years. Country specific costs of a sodium reduction policy were estimated using the WHO Noncommunicable Disease Costing Tool. Country…
Government/Law | Chronic Disease/Risk | Cost-Effectiveness Analysis | Child/Nutrition | Social Determinants | Policy/Regulation | Food/Agriculture | Health/Medicine | Global -
Lesson/ModuleWeb Portal, Teaching Resource 2016Placing a Bet: New Therapy for Parkinson's Disease
This module is intended for use by business school students. It examines the decision-making process …
This module is intended for use by business school students. It examines the decision-making process at a pharmaceutical company as its chief operating officer decides whether to invest in the development and licensing of a promising treatment for Parkinson’s disease. The module is structured around a drug development case that provides students with opportunities to: (1) analyze a rich and realistic description of the complex scientific and medical results associated with a promising therapeutic molecule…
Government/Law | Chronic Disease/Risk | Test Performance | Technology Assessment | Policy/Regulation | Business/Industry | Health/Medicine | Science/Technology | Global | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
Lesson/ModuleWeb Portal, Teaching Resource 2016Educational Module: Drug-Induced Birth Defects
Using the currently topical issue of whether SSRI (Selective Serotonin Reuptake Inhibitor) anti-depressants cause birth …
Using the currently topical issue of whether SSRI (Selective Serotonin Reuptake Inhibitor) anti-depressants cause birth defects, the module aims to provide students with a general understanding of the following: (1) human risk factor causation as determined by epidemiologic methods; (2) the limits of non-human toxicological evidence to the assessment of causality in humans; (3) the importance of pharmacovigilance for all medications; (4) special difficulties in identifying causes of human birth defects; (5) the importance of…
Government/Law | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Risk Analysis | Child/Nutrition | Health/Medicine | Science/Technology | Global | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Quantitative Literacy